Lung Cancer Foundation of America logo
Donate
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • The First 7 Days Podcast
    • Survivor Stories
    • Tributes
    • Hope With Answers℠ Videos
    • Hope With Answers℠ Podcast
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy
  • Hope
  • Research
  • Life
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • The First 7 Days Podcast
    • Survivor Stories
    • Tributes
    • Hope With Answers℠ Videos
    • Hope With Answers℠ Podcast
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy
  • Donate
  • Hope
  • Research
  • Life

What Can We Help You Find?

  • How to detect lung cancer
    • How do you know if you are at risk for lung cancer?
    • 7 Signs of Lung Cancer You Should Know – OLD
    • Types of lung cancer
  • Understanding diagnosis
    • What Do I Need To Know About Genetic Mutation Testing?
    • I Am Going to Have My Tumor Tested for Mutations, What Should I Expect From the Procedure?
    • What If I’m Told I Can’t Get My Tumor Tested?
    • What is ALK-positive lung cancer?
    • What is EGFR-positive lung cancer and how is it treated?
    • What is ROS1-positive lung cancer and how is it treated?
    • Small Cell Lung Cancer Research: What You Need To Know
  • What are the latest treatments available besides chemotherapy and radiation?
    • Targeted Therapies
    • What Targeted Therapies Are Currently Available?
    • Immunotherapies
    • Should I be seeking a second opinion?
    • Is There a Type of Physician That Specializes in the Treatment of Lung Cancer?
    • I Have Found a Thoracic Oncologist That I Feel Comfortable With, What Is Next?
  • Lung Cancer Facts: 29 Statistics and Figures
  • Lung Cancer Resources

The National Lung Screening Trial (NLST) Results Regarding Early Detection

National Lung Screening Trial:

The release, in 2010,  by the National Cancer Institute (NCI) of the results of its eight year National Lung Screening Trial (NLST) remains an exciting research development for those at risk for lung cancer and early detection. While a success story in many respects it is also at this juncture limited in its scope and application. Much more needs to be done not only with interpreting the NLST but developing other safe, low cost methods of early detection.

The NLST enrolled 53,000 current and former smokers between the ages of 55 and 74. The initial results concluded that yearly CT scans reduced the mortality rate of lung cancer by 20 percent. The NCI noted that it was the first time there has been “clear evidence of a significant reduction in lung cancer mortality with a screening test in a randomized controlled trial.” 20 percent is a significant number when weighed against the reality of yearly deaths of men and women from lung cancer in excess of 150,000.

CT Scan

U.S. PREVENTIVE SERVICES TASK FORCE (USPSTF) RECOMMENDATION

The U.S. Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without related signs or symptoms.

It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in its assessment.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.

As a result of the National Lung Screening Trial, the USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

NLST is a significant step in the right direction, not simply because of the results but for the fact that it showcases the importance of lung cancer research and that great strides are possible when funding is made available for lung cancer research.

 

While the NLST at present is the only definitive and positive research for the early detection of lung cancer there are other promising and interesting research programs for early detection underway. These include a blood test that detects a protein that could be used to detect lung cancer; the use of so-called sniffer dogs; the use of cells from the interior of the nose; breathalyzers; and, sputum tests to name a few.

Read about the National Lung Screening Trial (NLST) here.

Read the entire Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement here.

You might find this interesting

Donate Online

Your donation to Lung Cancer Foundation of America will help to fund research that will find new treatments for lung cancer patients everywhere.

I want to give in honor of...

name or relation

Donation Amount

other amount

More

  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Milestones
    • Newsroom
    • Community Outreach
    • Sponsors
    • Contact Us
    • Legal
  • About Lung Cancer
    • Types of Lung Cancer
    • Detection
    • Diagnosis
    • Treatment
    • Lung Cancer Facts
    • Lung Cancer Resources
  • Research
    • Latest Research
    • Clinical Trials
    • Grant Opportunities
    • Grant Recipients
    • Meet the Investigators
  • Living with Lung Cancer
    • The First 7 Days Podcast
    • Survivor Stories
    • Tributes
    • Hope With Answers℠ Videos
    • Hope With Answers℠ Podcast
  • Get Involved
    • Lung Cancer Awareness Month
    • Join Us
    • Contribute
    • Events
    • Advocacy

Our Mission

LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

While raising funds to support lung cancer research, LCFA will raise the public’s awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.



Latest In Research

03/2
2021

Merck Pulls Keytruda for SCLC

From Biospace Merck pulls Keytruda for SCLC: On March 1, 2021, pharmaceutical company, Merck announced plans to pull Ketruda for SCLC. Merck's Keytruda (pembrolizumab) is the dominant checkpoint inhibitor in the immuno-oncology spac…

Sign up

Get the latest news about lung cancer research.

Connect with us



©2021 Lung Cancer Foundation of America. All Rights Reserved. EIN 20-8730839

Sponsors    |    Legal and Privacy    |    Media Contact    |   State Fundraising Notices